Movement Alert｜Luye Pharma Falls 6.91% in Regular Trading, Innovative Drug Sector Under Sustained Pressure

Market Focus06-30

On June 30, Luye Pharma declined 6.91% in regular trading, trading at HK$1.76/share, with turnover of HK$107 million.

On the news front, the innovative drug sector continues to face broad-based selling pressure, with the Hang Seng Stock Connect Innovative Drug Index retreating to levels seen before last year's sector rally. Luye Pharma had previously surged over 7% on June 17 following positive Phase 2 clinical data for its core pipeline drug LY03015, a novel VMAT2 inhibitor/Sigma-1R agonist for tardive dyskinesia. That catalyst has now been fully digested, with the stock giving back gains over subsequent sessions.

Within the Pharmaceuticals sector, the overall tone remained weak. Among peers, CSPC Pharma fell 1.68%, Hengrui Pharma fell 1.72%, SBP Group fell 1.56%, Hansoh Pharma fell 2.64%, and Asymchem fell 5.42%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1117378377?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-30 10:55","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1117378377","market":"us","top_or_hot":-1,"title":"Movement Alert｜Luye Pharma Falls 6.91% in Regular Trading, Innovative Drug Sector Under Sustained Pressure","media":"Market Focus","content":"<p><p>On June 30, Luye Pharma declined 6.91% in regular trading, trading at HK$1.76/share, with turnover of HK$107 million.</p><p>On the news front, the innovative drug sector continues to face broad-based selling pressure, with the Hang Seng Stock Connect Innovative Drug Index retreating to levels seen before last year's sector rally. Luye Pharma had previously surged over 7% on June 17 following positive Phase 2 clinical data for its core pipeline drug LY03015, a novel VMAT2 inhibitor/Sigma-1R agonist for tardive dyskinesia. That catalyst has now been fully digested, with the stock giving back gains over subsequent sessions.</p><p>Within the Pharmaceuticals sector, the overall tone remained weak. Among peers, CSPC Pharma fell 1.68%, Hengrui Pharma fell 1.72%, SBP Group fell 1.56%, Hansoh Pharma fell 2.64%, and Asymchem fell 5.42%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Luye Pharma Falls 6.91% in Regular Trading, Innovative Drug Sector Under Sustained Pressure</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Luye Pharma Falls 6.91% in Regular Trading, Innovative Drug Sector Under Sustained Pressure\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-30 10:55</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 30, Luye Pharma declined 6.91% in regular trading, trading at HK$1.76/share, with turnover of HK$107 million.</p><p>On the news front, the innovative drug sector continues to face broad-based selling pressure, with the Hang Seng Stock Connect Innovative Drug Index retreating to levels seen before last year's sector rally. Luye Pharma had previously surged over 7% on June 17 following positive Phase 2 clinical data for its core pipeline drug LY03015, a novel VMAT2 inhibitor/Sigma-1R agonist for tardive dyskinesia. That catalyst has now been fully digested, with the stock giving back gains over subsequent sessions.</p><p>Within the Pharmaceuticals sector, the overall tone remained weak. Among peers, CSPC Pharma fell 1.68%, Hengrui Pharma fell 1.72%, SBP Group fell 1.56%, Hansoh Pharma fell 2.64%, and Asymchem fell 5.42%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02186","symbol_name":"绿叶制药","start_time":0,"source_url":"","article_id":"1117378377","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1117378377","pubTimestamp":1782788114,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 30, Luye Pharma declined 6.91% in regular trading, trading at HK$1.76/share, with turnover of HK$107 million.On the news front, the innovative drug sector continues to face broad-based...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02186":"绿叶制药"},"translate_title":"动静快讯|绿叶制药常规交易跌6.91%创新药板块持续承压","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02186":1},"content_text":"On June 30, Luye Pharma declined 6.91% in regular trading, trading at HK$1.76/share, with turnover of HK$107 million.On the news front, the innovative drug sector continues to face broad-based selling pressure, with the Hang Seng Stock Connect Innovative Drug Index retreating to levels seen before last year's sector rally. Luye Pharma had previously surged over 7% on June 17 following positive Phase 2 clinical data for its core pipeline drug LY03015, a novel VMAT2 inhibitor/Sigma-1R agonist for tardive dyskinesia. That catalyst has now been fully digested, with the stock giving back gains over subsequent sessions.Within the Pharmaceuticals sector, the overall tone remained weak. Among peers, CSPC Pharma fell 1.68%, Hengrui Pharma fell 1.72%, SBP Group fell 1.56%, Hansoh Pharma fell 2.64%, and Asymchem fell 5.42%.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1117378377","isCrawlerRequest":true}